Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic drum debarments

Executive Summary

Denial of hearings and final debarment orders issued for Charles DiCola, former VP-operations at Bolar Pharmaceutical; Liaquat Hossain, former manager of product development at Superpharm; and Daphne Pai, former VP-regulatory affairs & quality control at American Therapeutics, a Nov. 5 Federal Register notice states. In separate requests for hearings, the plaintiffs argued that debarment violated the ex post facto clause of the U.S. Constitution. FDA maintains that since the intent behind section 306(a) (2) of the FD&C act is remedial, rather than punitive, debarment does not violate the ex post facto clause of the fourth.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel